Evidence map›Paper›PMID 28376728›Full record

ArticleBMC cancer2017

Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.

Bojana Jovanović, Quanhu Sheng, Robert S Seitz, Kasey D Lawrence, Stephan W Morris, Lance R Thomas, David R Hout, Brock L Schweitzer, Yan Guo, Jennifer A Pietenpol and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00930930 (A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00930930 phase2completednot on this map

A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.

TypeinterventionalSponsorVanderbilt-Ingram Cancer CenterRan2009 to 2014Enrolled145ConditionsBreast CancerArmscisplatin, everolimus, paclitaxel, placebo, Venous blood draw
3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. SenescentMicroorganisms · 2026
    Article
  2. Article
  3. Genomic and immune profiling of breast cancer brain metastases.Acta neuropathologica communications · 2025
    Article
  4. Review
  5. Article
  6. Comparison of RNA-Sequencing Methods for Degraded RNA.International journal of molecular sciences · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bojana JovanovićMedical Oncology Department, Dana-Farber Cancer Institute, Harvard Medical School and Broad Institute, Boston, 02215, MA, USA.
Quanhu ShengCenter for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, 37232, TN, USA.
Robert S SeitzInsight Genetics Incorporated, Nashville, 37217, TN, USA.
Kasey D LawrenceInsight Genetics Incorporated, Nashville, 37217, TN, USA.
Stephan W MorrisInsight Genetics Incorporated, Nashville, 37217, TN, USA.
Lance R ThomasInsight Genetics Incorporated, Nashville, 37217, TN, USA.
David R HoutInsight Genetics Incorporated, Nashville, 37217, TN, USA.
Brock L SchweitzerInsight Genetics Incorporated, Nashville, 37217, TN, USA.
Yan GuoCenter for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, 37232, TN, USA.
Jennifer A PietenpolDepartment of Biochemistry, Vanderbilt University, Nashville, 37232, TN, USA.
Brian D LehmannDepartment of Biochemistry, Vanderbilt University, Nashville, 37232, TN, USA. brian.d.lehmann@vanderbilt.edu.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131
6 · The paper itself

Abstract

backgroundTriple negative breast cancer (TNBC) is a heterogeneous disease that lacks unifying molecular alterations that can guide therapy decisions. We previously identified distinct molecular subtypes of TNBC (TNBCtype) using gene expression data generated on a microarray platform using frozen tumor specimens. Tumors and cell lines representing the identified subtypes have distinct enrichment in biologically relevant transcripts with differing sensitivity to standard chemotherapies and targeted agents. Since our initial discoveries, RNA-sequencing (RNA-seq) has evolved as a sensitive and quantitative tool to measure transcript abundance.

methodsTo demonstrate that TNBC subtypes were similar between platforms, we compared gene expression from matched specimens profiled by both microarray and RNA-seq from The Cancer Genome Atlas (TCGA). In the clinical care of patients with TNBC, tumor specimens collected for diagnostic purposes are processed by formalin fixation and paraffin-embedding (FFPE). Thus, for TNBCtype to eventually have broad and practical clinical utility we performed RNA-seq gene expression and molecular classification comparison between fresh-frozen (FF) and FFPE tumor specimens.

resultsAnalysis of TCGA showed consistent subtype calls between 91% of evaluable samples demonstrating conservation of TNBC subtypes across microarray and RNA-seq platforms. We compared RNA-seq performed on 21-paired FF and FFPE TNBC specimens and evaluated genome alignment, transcript coverage, differential transcript enrichment and concordance of TNBC molecular subtype calls. We demonstrate that subtype accuracy between matched FF and FFPE samples increases with sequencing depth and correlation strength to an individual TNBC subtype.

conclusionsTNBC subtypes were reliably identified from FFPE samples, with highest accuracy if the samples were less than 4 years old and reproducible subtyping increased with sequencing depth. To reproducibly subtype tumors using gene expression, it is critical to select genes that do not vary due to platform type, tissue processing or RNA isolation method. The majority of differentially expressed transcripts between matched FF and FFPE samples could be attributed to transcripts selected for by RNA enrichment method. While differentially expressed transcripts did not impact TNBC subtyping, they will provide guidance on determining which transcripts to avoid when implementing a gene set size reduction strategy.

trial registrationNCT00930930 07/01/2009.

Indexed as

High-Throughput Nucleotide SequencingFemaleFormaldehydeGene Expression Regulation, NeoplasticHumansNeoplasm ProteinsParaffin EmbeddingRNATissue FixationTriple Negative Breast NeoplasmsFormaldehydeNeoplasm ProteinsRNAFormalin-fixed paraffin embeddedFresh-frozenRNA-seqTNBCtype

Identifiers

PMID28376728
PMCPMC5379658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.